ProfileGDS5678 / 1455001_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 95% 97% 96% 95% 95% 95% 96% 96% 95% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.6384596
GSM967853U87-EV human glioblastoma xenograft - Control 28.8836296
GSM967854U87-EV human glioblastoma xenograft - Control 38.7037595
GSM967855U87-EV human glioblastoma xenograft - Control 49.3252997
GSM967856U87-EV human glioblastoma xenograft - Control 58.9401896
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3271895
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.3798195
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5549195
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.7566796
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.6702896
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.5843895
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.7833696
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.7230396
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.0316196